The Sleepless Brain: Neuroimaging Support for a Differential Diagnosis of Insomnia (SOMNET)
Primary Purpose
Insomnia
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
MRI
Sponsored by
About this trial
This is an interventional basic science trial for Insomnia focused on measuring Insomnia, Hyperarousal
Eligibility Criteria
Inclusion Criteria:
- Insomnia group: patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning.
- control group: no self-reported sleep problems in the last 2 months.
- 20-50 years old.
- Male or female.
- having given written informed consent to participate in the research project.
Exclusion Criteria:
- Night and shift-workers.
- Psychiatric disorder: clinical mood disorder, anxiety disorder, psychosis, bipolar disorder.
- For insomnia group: all sleep disorders other than persistent insomnia.
- For control group: all sleep disorders.
- Progressive neurological diseases that include restless legs syndrome.
- Cardiovascular disease other than treated hypertension.
- Unstable respiratory or endocrinological diseases.
- Drug addiction, alcohol addiction during the previous 6 months.
- Having undertaken trans-meridian travel (± 3H) in the previous 1 month.
- Pregnant or lactating women.
- Chronic pain.
- Hypnotic and psychotropic medication taking or stopped less than 5 half-life periods of molecules before screening V0.
- Patient participating to any other interventional study.
- For MRI: presence of a ferromagnetic foreign body (in particular certain intracranial clips, certain cardiac valves, intraocular foreign body, or subject having worked with metals), the presence of an implanted pacemaker, subject with cardiac or brain valves of ventricular derivation (risk of maladjustment), claustrophobia.
Sites / Locations
- CHU de Bordeaux
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Insomnia group
Control group
Arm Description
Patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning, objectified low sleep quality (SE <85%) with 10 days actigraphy occurred in the last 2 months
Volunteer without sleep problems either self-reported or objectified through actigraphy (SE ≥85%)
Outcomes
Primary Outcome Measures
Resting state intrinsic connectivity within the emotion processing network by MRI
Secondary Outcome Measures
Total sleep time obtained by actimetry
Sleep efficiency obtained by actimetry
Wake after sleep onset obtained by actimetry
Sleep latency obtained by actimetry
Total sleep time obtained by sleep diary
Sleep efficiency obtained by sleep diary
Wake after sleep onset obtained by sleep diary
sleep latency obtained by sleep diary
Questionnaire regarding sleep problems : Pittsburgh Sleep Questionaire (PSQ)
Questionnaire regarding sleep problems : Insomnia Severity Index (ISI)
Questionnaire regarding depression : Beck Depression Inventory (BDI)
Questionnaire regarding anxiety : Beck Anxiety Inventory (BAI)
Questionnaire regarding arousal : Arousal Predisposition Scale (APS)
Questionnaire regarding sleep reactivity : Ford Insomnia Response to Stress Test (FIRST)
Questionnaire regarding presleep arousal state : Presleep State Arousal Scale (PSAS)
Questionaire regarding emotional state : Positive and Negative Affect Schedule (PANAS)
Full Information
NCT ID
NCT02821234
First Posted
June 17, 2016
Last Updated
August 22, 2017
Sponsor
University Hospital, Bordeaux
Collaborators
Institut des Maladies Neurodégénératives (UMR5293)
1. Study Identification
Unique Protocol Identification Number
NCT02821234
Brief Title
The Sleepless Brain: Neuroimaging Support for a Differential Diagnosis of Insomnia
Acronym
SOMNET
Official Title
The Sleepless Brain: Neuroimaging Support for a Differential Diagnosis of Insomnia
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
September 1, 2016 (Actual)
Primary Completion Date
April 3, 2017 (Actual)
Study Completion Date
April 3, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux
Collaborators
Institut des Maladies Neurodégénératives (UMR5293)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
One-tenth of the population suffers from insomnia, increasing their risk on other health problems such as depression. Self-reported sleep quality only was historically leading for insomnia diagnosis, but more recently a state of 24-hour hyperarousal has been associated with insomnia, either physiological (increased heart rate, higher frequency EEG) or predominant cognitive-emotional hyperarousal (worry, rumination, repetitive thoughts). Strong evidence shows that those suffering from insomnia with physiological hyperarousal are at higher risk of short and long term severe health problems such as inflammation and hypertension than the group without physiological hyperarousal. The neurophysiological basis of these insomnia phenotypes has however barely been investigated, although its results can have major consequences for how this limiting condition will be treated.
To support the development of a differential diagnosis of insomnia, structural and functional brain connectivity in insomnia patients with different levels of hyperarousal will be investigated and related to sleep variables. Investigators will compare the insomnia group to a normal sleeping control group. Investigators expect that the emotion processing circuit (amygdala-ventromedial prefrontal cortex) is a) more affected in insomniacs compared to normal sleeping controls and b) the directionality of this effect to depend on the level and type of hyperarousal in insomniacs. Further, investigators expect c) amygdala activity to be positive correlated with physiological hyperarousal level and d) prefrontal activity to be positively correlated with cognitive-emotional hyperarousal level. Investigators expect a higher physiological hyperarousal level to be reflected in affected afferent pathways of the amygdala towards the ventromedial prefrontal cortex and investigators expect higher cognitive-emotional hyperarousal to be related to affected efferent pathways from the ventromedial prefrontal cortex to the amygdala. Investigators expect sleep quality to play a mediating role in both types of hyperarousal and their brain activation patterns in insomnia patients and normal sleeping controls.
These data can lead to the definition of new insomnia phenotypes and to new customized and effective insomnia treatment, focused not only on improving sleep but also on changing dysfunctional hyperarousal levels that currently put insomniacs at risk of numerous severe health problems.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia
Keywords
Insomnia, Hyperarousal
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Insomnia group
Arm Type
Experimental
Arm Description
Patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning, objectified low sleep quality (SE <85%) with 10 days actigraphy occurred in the last 2 months
Arm Title
Control group
Arm Type
Experimental
Arm Description
Volunteer without sleep problems either self-reported or objectified through actigraphy (SE ≥85%)
Intervention Type
Other
Intervention Name(s)
MRI
Primary Outcome Measure Information:
Title
Resting state intrinsic connectivity within the emotion processing network by MRI
Time Frame
During Visit V2 (study termination), up to 3 month after consent signature
Secondary Outcome Measure Information:
Title
Total sleep time obtained by actimetry
Time Frame
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Title
Sleep efficiency obtained by actimetry
Time Frame
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Title
Wake after sleep onset obtained by actimetry
Time Frame
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Title
Sleep latency obtained by actimetry
Time Frame
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Title
Total sleep time obtained by sleep diary
Time Frame
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Title
Sleep efficiency obtained by sleep diary
Time Frame
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Title
Wake after sleep onset obtained by sleep diary
Time Frame
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Title
sleep latency obtained by sleep diary
Time Frame
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Title
Questionnaire regarding sleep problems : Pittsburgh Sleep Questionaire (PSQ)
Time Frame
During Pre-inclusion Visit, at consent signature
Title
Questionnaire regarding sleep problems : Insomnia Severity Index (ISI)
Time Frame
During Pre-inclusion Visit, at consent signature
Title
Questionnaire regarding depression : Beck Depression Inventory (BDI)
Time Frame
During Pre-inclusion Visit, at consent signature
Title
Questionnaire regarding anxiety : Beck Anxiety Inventory (BAI)
Time Frame
During Pre-inclusion Visit, at consent signature
Title
Questionnaire regarding arousal : Arousal Predisposition Scale (APS)
Time Frame
During Inclusion Visit, up to 1 month after consent signature
Title
Questionnaire regarding sleep reactivity : Ford Insomnia Response to Stress Test (FIRST)
Time Frame
During Inclusion Visit, up to 1 month after consent signature
Title
Questionnaire regarding presleep arousal state : Presleep State Arousal Scale (PSAS)
Time Frame
During Visit V2 (study termination), up to 3 month after consent signature
Title
Questionaire regarding emotional state : Positive and Negative Affect Schedule (PANAS)
Time Frame
During Visit V2 (study termination), up to 3 month after consent signature
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Insomnia group: patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning.
control group: no self-reported sleep problems in the last 2 months.
20-50 years old.
Male or female.
having given written informed consent to participate in the research project.
Exclusion Criteria:
Night and shift-workers.
Psychiatric disorder: clinical mood disorder, anxiety disorder, psychosis, bipolar disorder.
For insomnia group: all sleep disorders other than persistent insomnia.
For control group: all sleep disorders.
Progressive neurological diseases that include restless legs syndrome.
Cardiovascular disease other than treated hypertension.
Unstable respiratory or endocrinological diseases.
Drug addiction, alcohol addiction during the previous 6 months.
Having undertaken trans-meridian travel (± 3H) in the previous 1 month.
Pregnant or lactating women.
Chronic pain.
Hypnotic and psychotropic medication taking or stopped less than 5 half-life periods of molecules before screening V0.
Patient participating to any other interventional study.
For MRI: presence of a ferromagnetic foreign body (in particular certain intracranial clips, certain cardiac valves, intraocular foreign body, or subject having worked with metals), the presence of an implanted pacemaker, subject with cardiac or brain valves of ventricular derivation (risk of maladjustment), claustrophobia.
Facility Information:
Facility Name
CHU de Bordeaux
City
Bordeaux
ZIP/Postal Code
33000
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
33772591
Citation
Sanz-Arigita E, Daviaux Y, Joliot M, Dilharreguy B, Micoulaud-Franchi JA, Bioulac S, Taillard J, Philip P, Altena E. Brain reactivity to humorous films is affected by insomnia. Sleep. 2021 Sep 13;44(9):zsab081. doi: 10.1093/sleep/zsab081.
Results Reference
derived
Learn more about this trial
The Sleepless Brain: Neuroimaging Support for a Differential Diagnosis of Insomnia
We'll reach out to this number within 24 hrs